All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Visual abstract | AGILE study of ivosidenib + azacitidine versus placebo + azacitidine in newly diagnosed patients with an IDH1 mutation

Jan 28, 2022

Bookmark this article

The AML Hub is happy to present a Visual Abstract representing key data from the phase III AGILE study, evaluating ivosidenib + azacitidine vs placebo + azacitidine in patients with previously untreated IDH1-mutant acute myeloid leukemia (AML).


Visual Abstract Download!

Click here to download this visual abstract

Click To Download



Subscribe to get the best content related to AML delivered to your inbox